Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the "European Paediatric Oncology Off-patents Medicines Consortium" (EPOC) Trial.

Abstract:

BACKGROUND AND OBJECTIVES:Doxorubicin plays an essential role in the treatment of paediatric cancers. Defining genotypes with a higher risk for developing anthracycline-induced cardiotoxicity could help to reduce cardiotoxicity. METHODS:Data originated from a phase II study assessing the pharmacokinetics of doxorubicin in 100 children. Studied patients (0-17 years) were treated for solid tumours or leukaemia. Two cycles of doxorubicin were studied. Concentrations of natriuretic peptides proANP, BNP and NT-proBNP and cardiac troponins T and I were measured at five time points before, during and after two cycles of doxorubicin treatment. Genotypes of 17 genetic polymorphisms in genes encoding for anthracycline metabolizing enzymes and drug transporters were determined for each patient. We analysed the influence of genotypes on cardiac biomarker concentrations at different time points by a Kruskal-Wallis test. To perform a pairwise comparison significant genetic polymorphisms with more than two genotypes were analysed by a post hoc test. RESULTS:The Kruskal-Wallis tests and the post hoc-tests showed a significant association for seven genetic polymorphisms (ABCB1-rs1128503, ABCB1-rs1045642, ABCC1-rs4148350, CBR3-rs8133052, NQO2-in/del, SLC22A16-rs714368 and SLC22A16-rs6907567) with the concentration of at least one biomarker at one or more time points. We could not identify any polymorphism with a consistent effect on any biomarker over the whole treatment period. CONCLUSIONS:In this study of patients treated with doxorubicin for different tumour entities, seven genetic polymorphisms possibly influencing the pharmacokinetics and pharmacodynamics of doxorubicin could lead occasionally to differences in the concentration of cardiac biomarkers. Since, the role of cardiac biomarkers for monitoring anthracycline-induced cardiotoxicity has not yet been clarified, further trials with a long follow-up time are required to assess the impact of these genetic polymorphisms on chemotherapy-related cardiotoxicity. TRIAL REGISTRATION:EudraCT number: 2009-011454-17.

authors

Hellmann F,Völler S,Krischke M,Jamieson D,André N,Bisogno G,Boddy A,Hempel G

doi

10.1007/s13318-019-00592-6

subject

Has Abstract

pub_date

2020-06-01 00:00:00

pages

413-422

issue

3

eissn

0378-7966

issn

2107-0180

pii

10.1007/s13318-019-00592-6

journal_volume

45

pub_type

杂志文章
  • Hepatobiliary transport of YM466, a novel factor Xa inhibitor, in rats.

    abstract::YM466, a novel factor Xa inhibitor, is a hydrophilic compound with a carboxylic acid moiety. Previous studies in rats have shown that YM466 does nor undergo metabolism but is excreted into the bile and urine in unchanged form. Thus, in this study, we investigated in vivo hepatobiliary transport, focusing in particular...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/BF03191128

    authors: Mano Y,Usui T,Kamimura H

    更新日期:2006-04-01 00:00:00

  • Biopharmaceutical evaluation of time-controlled press-coated tablets containing polymers to adjust drug release.

    abstract::This paper deals with press-coated modified release tablets in which the drug dose is situated in the core or is divided between the core and the coat. The coat contains polymer (sodium alginate or hydroxypropylmethyl cellulose, HPMC) to control drug release. The main objective was to investigate how the pharmacokinet...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF03189338

    authors: Halsas M,Ervasti P,Veski P,Jürjenson H,Marvola M

    更新日期:1998-04-01 00:00:00

  • Pharmacokinetic plasma behaviors of intravenous and oral bioavailability of thymoquinone in a rabbit model.

    abstract::Thymoquinone (THQ), the active constituent of Nigella sativa seeds, has demonstrated some potential pharmacological activities. The present study was designed to investigate the pharmacokinetic behavior of THQ following intravenous (IV) and oral (PO) administration using an animal model. THQ was given vascularly (5 mg...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/s13318-014-0207-8

    authors: Alkharfy KM,Ahmad A,Khan RM,Al-Shagha WM

    更新日期:2015-09-01 00:00:00

  • Functional characterization of cynomolgus monkey UDP-glucuronosyltransferase 1A9.

    abstract::UDP-glucuronosyltransferase 1A9 (UGT1A9) contributes to the glucuronidation of numerous drugs. Cynomolgus monkeys are regarded as experimental animals similar to humans in studies on safety evaluation and biotransformation for drug development. In this study, the similarities and differences in the enzymatic propertie...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/s13318-014-0177-x

    authors: Yamamoto K,Mukai M,Nagaoka K,Hayashi K,Hichiya H,Okada K,Murata M,Shigeyama M,Narimatsu S,Hanioka N

    更新日期:2014-09-01 00:00:00

  • Inhibition of diazepam metabolism in microsomal- and perfused liver preparations of the rat by desmethyldiazepam, N-methyloxazepam and oxazepam.

    abstract::Hydroxylated metabolites of diazepam can be conjugated and are therefore generally thought not to affect the metabolism of diazepam. Liver microsomes, obtained from phenobarbital-pretreated rats, showed an inhibition of diazepam (10(-5) M) metabolism by desmethyldiazepam as well as by N-methyloxazepam or oxazepam (5 X...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/BF03189692

    authors: Savenije-Chapel EM,Bast A,Noordhoek J

    更新日期:1985-01-01 00:00:00

  • Evaluation of Strategies for the Assessment of Drug-Drug Interactions Involving Cytochrome P450 Enzymes.

    abstract:BACKGROUND AND OBJECTIVES:Drug-drug interactions (DDIs) can occur when one drug alters the metabolism of another drug. Drug metabolism mediated by cytochrome P450 enzymes (CYPs) is responsible for the majority of metabolism of known drugs and inhibition of CYP enzymes is a well-known cause of DDIs. In the current study...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/s13318-018-0485-7

    authors: Reinen J,Smit M,Wenker M

    更新日期:2018-12-01 00:00:00

  • The pharmacokinetics of lisuride hydrogen maleate in rat, rabbit and rhesus monkey.

    abstract::The pharmacokinetics of lisuride hydrogen maleate (LHM) were investigated in rat, rabbit and rhesus monkey. Experiments were designed to meet not only the requirements of drug registration but also to serve other preclinical disciplines (toxicology, pharmacology). LHM is absorbed almost completely at a dose level of 1...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/BF03189490

    authors: Humpel M,Toda T,Oshino N,Pommerenke G

    更新日期:1981-01-01 00:00:00

  • Intraocular penetration of fusidic acid with topical Fucithalmic.

    abstract::Fucithalmic is a newly developed 1% microcrystalline suspension of the antistaphylococcal antibiotic fusidic acid. Penetration into the eye was investigated in twenty patients about to undergo cataract extraction. A single dose produced median antibiotic levels in the aqueous humour of 0.3 mcg/ml, maintained for at le...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/BF03189761

    authors: Hansen S

    更新日期:1985-10-01 00:00:00

  • An attempt to establish an in vitro-in vivo correlation: case of paracetamol immediate-release tablets.

    abstract::The purpose of this study was to investigate the possibility of developing different levels of in vitro-in vivo correlation for immediate-release paracetamol tablets using in vitro dissolution data obtained under various experimental conditions. The influence of agitation intensity and pH value of the dissolution medi...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/BF03189824

    authors: Radovanović J,Durić Z,Jovanović M,Ibrić S,Petrović M

    更新日期:1998-01-01 00:00:00

  • Genetic CYP2C19 polymorphism dependent non-responders to clopidogrel therapy--does structural design, dosing and induction strategies have a role to play?

    abstract::Recent evidences suggest that genetic CYP2C19 polymorphism plays a role in the development of treatment resistance for clopidogrel's antiplatelet therapy. This short communication puts forward some strategies that could be potentially used to overcome the genetic polymorphism associated hurdles. While there is some es...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/BF03191165

    authors: Srinivas NR

    更新日期:2009-07-01 00:00:00

  • Statistical aspects of bioequivalence testing between two medicinal products.

    abstract::A generic drug product (test product) is bioequivalent to an innovator product (reference product) when their bioavailabilities in the same molar dose are similar. Bioavailability is expressed by pharmacokinetic parameters such as the area under plasma concentration-time curve (AUC), the maximum plasma concentration (...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/BF03226406

    authors: Zintzaras E

    更新日期:2005-01-01 00:00:00

  • Effect of induced hypoalbuminemia on distribution, total clearance and unbound clearance of piroxicam in vivo in the rat.

    abstract::The influence of decreased albumin concentration on the pharmacokinetic behaviour of Piroxicam was studied in vivo in rats that had undergone plasmapheresis. Reductions of approximately 25% and 50% in the plasma albumin concentration were achieved, the former in rats not given plasma expander, the latter in animals gi...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/BF03188792

    authors: Troconiz JI,Lopez-Bustamante LG,Fos D

    更新日期:1993-04-01 00:00:00

  • Metabolism of (-)-(S)-nicotine in the isolated perfused rabbit lung.

    abstract::The metabolism of (-)-(S)-nicotine has been investigated following intratracheal administration to the recirculating perfused rabbit lung model. The metabolic products present in the perfusate were identified by co-chromatography (HPLC and GC) with authentic standards and quantified by HPLC. After the 180 min perfusio...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/BF03190976

    authors: Aislaitner G,Bello A,Tan SC,Hutt AJ,Marriott C,Gorrod JW

    更新日期:1997-10-01 00:00:00

  • The sojourn time and its use in pharmacology.

    abstract::A short review on some pharmacokinetic parameters (mean residence time, sojourn time, transit time) is given in relation to compartmental models and some examples and application are discussed. In particular the use of the sojourn time is suggested because this parameter can give useful informations when comparing the...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:

    authors: Segre G,Urso R

    更新日期:1991-01-01 00:00:00

  • Absolute bioavailability study in the dog with Visacor, a new cardioselective beta blocking drug with intrinsic sympathomimetic activity.

    abstract::The cardioselective beta-adrenergic blocking drug Visacor (ICI 141,292) was dosed to six beagle dogs in a randomized cross-over manner. Five formulations were examined i.e. a 15 mg/kg intravenous solution, a 50 mg/kg oral solution, and 50, 100 and 200 mg/kg oral powder formulations. Whole blood and urine samples were ...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/BF03189616

    authors: McAinsh J,Smith RP,Ferguson RA

    更新日期:1984-04-01 00:00:00

  • The effect of molecular weight on the biodistribution of hyaluronic acid radiolabeled with 111In after intravenous administration to rats.

    abstract::Hyaluronic acid (HA), is a high molecular weight (HMW) glucosaminoglycan with significant acitivity, and which influences a number of physiological and pathological processes such as tumorogenesis, arthritis, etc. The aim of this study was to determine the difference in the biodistributional pathways of 111In-labeled ...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/BF03191112

    authors: Svanovsky E,Velebny V,Laznickova A,Laznicek M

    更新日期:2008-07-01 00:00:00

  • Single Dose Oral and Intravenous Pharmacokinetics and Tissue Distribution of a Novel Hesperetin Derivative MTBH in Rats.

    abstract:BACKGROUND:MTBH, a novel hesperetin derivative, possesses in vivo hepatoprotective effects against carbon tetrachloride (CCl4)-induced acute liver injury in Institute of Cancer Research (ICR) mice. OBJECTIVES:This study investigated the pharmacokinetics and tissue distribution of MTBH and its conjugated metabolites in...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/s13318-015-0293-2

    authors: Shen C,Qian Z,Chen R,Meng X,Hu T,Chen Z,Li Y,Huang C,Hu C,Li J

    更新日期:2016-12-01 00:00:00

  • Pharmacokinetic and pharmacodynamic data and models in clinical trials.

    abstract::There is current emphasis for extended integration of pharmacokinetics (PK) and pharmacodynamics (PD) into all phases of new drug development, including large-scale clinical trials. In this paper, we focus on study design and data analysis issues for the investigation of pharmacokinetic/pharmacodynamic and blood level...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.1007/BF03220009

    authors: Steimer JL,Ebelin ME,Van Bree J

    更新日期:1993-01-01 00:00:00

  • Pharmacokinetics of vitexin-4″-O-glucoside in rats after intravenous application.

    abstract::Vitexin-4″-O-glucoside (VOG), being a main component in the leaves of Crataegus pinnatifida Bge. var. major, was isolated and then three different doses (20, 40, and 60 mg/kg) of VOG were administered intravenously to rats. To study its pharmacokinetics, a simple and rapid HPLC method was developed using hesperidin as...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/s13318-011-0071-8

    authors: Ying XX,Wang F,Cheng ZZ,Zhang WJ,Li HB,Du Y,Liu X,Wang SY,Kang TG

    更新日期:2012-06-01 00:00:00

  • In vivo metabolism of the anti-inflammatory agent 2-(5-ethylpyridin-2-yl)benzimidazole.

    abstract::The metabolic fate of anti-inflammatory agent 2-(5-ethylpyridin-2-yl)benzimidazole (KB-1043) was studied in rats after oral administration. An average of 12.2 +/- 1.5% of the dose was excreted in the urine in the course of 0-48 h; 56.7 +/- 2.6% with feces. Two metabolites were also detected in the urine and isolated b...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/BF03190109

    authors: Caputo O,Grosa G,Ceruti M,Viola F,Rocco F

    更新日期:1989-10-01 00:00:00

  • Hepatic metabolism of doxorubicin in mice and rats.

    abstract::We have studied the metabolism of doxorubicin in rat and mouse liver, heart and hepatocytes. Doxorubicinol was present in all cases at very low levels and 7-deoxyaglycones were present only in extraphysiological conditions: no aglycones were found either in fresh livers or in hearts of animals treated with the drug, b...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/BF03189834

    authors: Vrignaud P,Londos-Gagliardi D,Robert J

    更新日期:1986-04-01 00:00:00

  • Antioxidant action of a new flavonic derivative in acute carbon tetrachloride intoxication.

    abstract::The antioxidant potential of a new flavonic derivative named conventionally theophylline-rutoside [TR-1722] was estimated by the measurement of G-6-Pase activity (marker enzyme for the endoplasmic reticulum), catalase activity (enzyme involved in the antioxidant defence process), and total -SH groups from the hepatic ...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/BF03190270

    authors: Paduraru I,Saramet A,Danila G,Nichifor M,Jerca L,Iacobovici A,Ungureanu D,Filip M

    更新日期:1996-01-01 00:00:00

  • Prediction of the Oral Bioavailability Correlation Between Humans and Preclinical Animals.

    abstract:BACKGROUND:Experimental determination of a drug's oral bioavailability in humans is cost and time consuming; therefore, is usually performed on preclinical animals. It is believed that animal data are predictive of human data; however, there are some doubts regarding the reliability of this concept. The aim of this stu...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/s13318-020-00636-2

    authors: Beheshti S,Shayanfar A

    更新日期:2020-12-01 00:00:00

  • Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis.

    abstract::Pharmacokinetics of ketoprofen (KTP) enantiomers has been studied in patients with rheumatoid arthritis (RA) following administration of a single oral dose of 100 mg rac-KTP during multidrug therapy taking into consideration the genotype of RA patients Concentrations of (-)-R and (+)-S enantiomers of KTP in plasma, ur...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/s13318-011-0041-1

    authors: Główka F,Karaźniewicz-Łada M,Grześkowiak E,Rogozinska D,Romanowski W

    更新日期:2011-09-01 00:00:00

  • Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.

    abstract::Angiogenesis is integral to tumour growth and invasion, and is a key target for cancer therapeutics. However, for many of the licensed indications, only a modest clinical benefit has been observed for both monoclonal antibody and small-molecule tyrosine kinase inhibitor anti-angiogenic therapy. Pre-clinical and clinic...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.1007/s13318-017-0442-x

    authors: Morotti M,Dass PH,Harris AL,Lord S

    更新日期:2018-04-01 00:00:00

  • Pharmacokinetics of nefazodone in the dog following single oral administration.

    abstract::The pharmacokinetics of nefazodone (NEF) and two of its pharmacologically active metabolites viz hydroxynefazodone (HO-NEF) and m-chlorophenylpiperazine (mCPP) were determined following single oral administration of 100, 200 and 400 mg NEF to 6 beagle dogs in a three-way crossover study. Blood samples were collected f...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/BF03190163

    authors: Shukla UA,Marathe PH,Labudde JA,Pittman KA,Barbhaiya RH

    更新日期:1992-10-01 00:00:00

  • In vitro binding of lidocaine to liver tissue under the influence of propranolol: another mechanism of interaction?

    abstract::The co-administration of lidocaine and propranolol leads to significant drug-drug interactions. Beta-blockers decrease liver perfusion and inhibit the activity of hepatic microsomal lidocaine metabolizing enzymes of the P450_2D subfamily. Hence, there is a resulting reduction in the hepatic breakdown of lidocaine and ...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/BF03191006

    authors: Tesseromatis C,Kotsiou A,Tsagataki M,Tigka E,Vovou J,Alevizou A,Perisanidis C,Saranteas T,Karakitsos D,Karabinis A,Kostopanagiotou G

    更新日期:2007-10-01 00:00:00

  • Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine.

    abstract::The transdermally applied dopamine receptor agonist rotigotine is extensively metabolized in the liver. An open-label, parallel-group study was conducted to evaluate the effects of moderate hepatic impairment on the pharmacokinetics, safety and tolerability of rotigotine. Eight subjects with normal hepatic function an...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s13318-013-0153-x

    authors: Cawello W,Fichtner A,Boekens H,Braun M

    更新日期:2014-09-01 00:00:00

  • Multiplicative dependence of the first order rate constant and its impact on clinical pharmacokinetics and bioequivalence.

    abstract::The purpose of the study was to investigate the factors upon which the first order rate constant depends in order to assess the impact on the body-drug concentration when it changes throughout a treatment. A reasoning for linking the first order rate constants with several factors in a multiplicative way was proposed ...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/BF03190573

    authors: Fagiolino P

    更新日期:2004-01-01 00:00:00

  • Pharmacokinetics of pirazolac--a new anti-inflammatory drug--in human volunteers. I. Absorption, disposition, biotransformation and excretion.

    abstract::The absorption, disposition, biotransformation and excretion of the nonsteroidal anti-inflammatory drug pirazolac were investigated in 6 volunteers (3 males, 3 females, age 50 greater than years) after intravenous and oral administration of 50 mg 14C-pirazolac as an aqueous solution of the sodium salt. Pirazolac was v...

    journal_title:European journal of drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1007/BF03189696

    authors: Täuber U,Weiss C,Krause W,Acksteiner B,Matthes H

    更新日期:1985-01-01 00:00:00